Interactions between Siglec-8 and endogenous sialylated cis ligands restrain cell death induction in human eosinophils and mast cells
Frontiers in Immunology · 2023
DOI: 10.3389/fimmu.2023.1283370 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, 2023. Verfasst von Yun Cao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States. Hauptthemen laut MEDLINE: Eosinophils, Mast Cells. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Sialic acid-binding immunoglobulin-like lectin (Siglec)-8 is a sialoside-binding receptor expressed by eosinophils and mast cells that exhibits priming status- and cell type-dependent inhibitory activity. On eosinophils that have been primed with IL-5, GM-CSF, or IL-33, antibody ligation of Siglec-8 induces cell death through a pathway involving the β2 integrin-dependent generation of reactive oxygen species (ROS) via NADPH oxidase. In contrast, Siglec-8 engagement on mast cells inhibits cellular activation and mediator release but reportedly does not impact cell viability. The differences in responses between cytokine-primed and unprimed eosinophils, and between eosinophils and mast cells, to Siglec-8 ligation are not understood. We previously found that Siglec-8 binds to sialylated ligands present on the surface of the same cell (so-called cis ligands), preventing Siglec-8 ligand binding in trans. However, the functional relevance of these cis ligands has not been elucidated. We therefore explored the potential influence of cis ligands of Siglec-8 on both eosinophils and mast cells. De-sialylation using exogenous sialidase profoundly altered the consequences of Siglec-8 antibody engagement on both cell types, eliminating the need for cytokine priming of eosinophils to facilitate cell death and enabling Siglec-8–dependent mast cell death without impacting anti–Siglec-8 antibody binding. The cell death process licensed by de-sialylation resembled that characterized in IL-5–primed eosinophils, including CD11b upregulation, ROS production, and the activities of Syk, PI3K, and PLC. These results implicate cis ligands in restraining Siglec-8 function on eosinophils and mast cells and reveal a promising approach to the selective depletion of mast cells in patients with mast cell-mediated diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
- Department of Biomedical Engineering, Northwestern University McCormick School of Engineering, Evanston, IL, United States.
Förderung
- NHLBI NIH HHS
- NIAID NIH HHS
Zitieren
APA
Cao, Y., Rische, C. H., Bochner, B. S., & O'Sullivan, J. A. (2023). Interactions between Siglec-8 and endogenous sialylated cis ligands restrain cell death induction in human eosinophils and mast cells. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1283370
Vancouver
Cao Y, Rische CH, Bochner BS, O'Sullivan JA. Interactions between Siglec-8 and endogenous sialylated cis ligands restrain cell death induction in human eosinophils and mast cells. Frontiers in Immunology. 2023. doi:10.3389/fimmu.2023.1283370
BibTeX
@article{Cao2023,
author = {Cao, Yun and Rische, Clayton H and Bochner, Bruce S and O'Sullivan, Jeremy A},
title = {Interactions between Siglec-8 and endogenous sialylated cis ligands restrain cell death induction in human eosinophils and mast cells},
journal = {Frontiers in Immunology},
year = {2023},
doi = {10.3389/fimmu.2023.1283370}
}
EUVIMED